Liraglutide vs Survodutide (BI 456906)
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Liraglutide and Survodutide (BI 456906) (also searched as Survodutide (BI 456906) vs Liraglutide) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Liraglutide centers on metabolic, while Survodutide (BI 456906) leans toward metabolic. On indexed research, Survodutide (BI 456906) is ahead (Liraglutide: 22 studies, Human clinical; Survodutide (BI 456906): 26, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Liraglutide is strongest for metabolic; Survodutide (BI 456906) for metabolic.
- •Evidence: Liraglutide Human clinical (22 studies) vs Survodutide (BI 456906) Human clinical (26).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
GLP-1 Agonist | Type 2 Diabetes Management
GLP-1/Glucagon Agonist | Weight Loss & Diabetes
Liraglutide vs Survodutide (BI 456906): side-by-side
| Metric | Liraglutide | Survodutide (BI 456906) |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 22 | 26 |
| Research level | FDA Approved | Well Studied |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 1.0▲ | 0.0 |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 5.0▲ | 5.0▲ |
| Neuro & mood | 1.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 2.0▲ | 2.0▲ |
| Skin & aesthetics | 3.0▲ | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Liraglutide | Survodutide (BI 456906) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1/Glucagon receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~13 hours | — |
| Time to peak | 8–12 hours | — |
| Duration of action | 24 hours | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Liraglutide?
Liraglutide is a synthetic analog of human glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in glucose metabolism and appetite regulation. It acts as a GLP-1 receptor agonist, stimulating insulin secretion in response to elevated blood glucose levels while suppressing glucagon release, which helps lower blood sugar levels. Additionally, liraglutide slows gastric emptying and promotes satiety, contributing to weight loss in individuals with obesity or type 2 diabetes.
Full Liraglutide profile, mechanism & studies →What is Survodutide (BI 456906)?
Survodutide (BI 456906) is a novel dual agonist targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors. This peptide is under investigation primarily for its potential in treating obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The dual action of Survodutide aims to enhance weight loss while also improving glycemic control, which is particularly relevant in the context of type 2 diabetes and associated metabolic disorders.
Full Survodutide (BI 456906) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Liraglutide | 1.0/5 effect signal |
| Metabolic | Even | Both ~5.0/5 |
| Neuro | Liraglutide | 1.0/5 effect signal |
| Inflammation | Even | Both ~2.0/5 |
| Skin | Even | Both ~3.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Liraglutide and Survodutide (BI 456906)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Liraglutide vs Survodutide (BI 456906): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Liraglutide has 22 approved studies indexed (Human clinical), and Survodutide (BI 456906) has 26 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Liraglutide or Survodutide (BI 456906) better?
It depends on your goal. Liraglutide is strongest for metabolic; Survodutide (BI 456906) for metabolic. Survodutide (BI 456906) has more indexed studies (26). See the goal-by-goal breakdown above.
Is Liraglutide or Survodutide (BI 456906) better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Which has more research, Liraglutide or Survodutide (BI 456906)?
Liraglutide has 22 approved studies indexed (Human clinical); Survodutide (BI 456906) has 26 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Liraglutide and Survodutide (BI 456906)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Liraglutide vs Survodutide (BI 456906)?
Liraglutide: no community-reported effects logged yet. Survodutide (BI 456906): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Liraglutide or Survodutide (BI 456906) FDA-approved?
Liraglutide is FDA-approved. Survodutide (BI 456906) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Survodutide (BI 456906) better than Liraglutide?
For metabolic, Survodutide (BI 456906) has the edge; for metabolic, Liraglutide does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.